Dopamine-Enhancing Therapies and Risk of Neovascular AMD Conversion: A Target Trial Emulation
Listen to this summary
This study investigates whether dopamine-enhancing therapies, specifically levodopa ± carbidopa and dopamine receptor D2 (DRD2) agonists, are associated with a reduced risk of conversion from non-neovascular age-related macular degeneration (AMD) to neovascular AMD (nAMD). The findings indicate that levodopa ± carbidopa users experienced a significantly lower risk of conversion compared to matched controls, while no significant difference was observed for DRD2 agonist users. These results suggest that dopaminergic signaling may play a role in AMD progression, highlighting the need for further prospective research.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from American journal of ophthalmology
View all →Jun 24, 2026 · American journal of ophthalmology
Corneal Epithelial Alterations Associated With CDK4/6 Inhibitor Therapy in Hormone Receptor-Positive Breast Cancer
Jun 24, 2026 · American journal of ophthalmology
The Impact of PCSK9 Inhibitors on Development of Retinal Vascular Occlusions
Jun 23, 2026 · American journal of ophthalmology
Associations Between Routine Vaccinations and the Risk of New-Onset Idiopathic Uveitis
Jun 22, 2026 · American journal of ophthalmology
Association between statin use and dry eye disease: A systematic review and meta-analysis
Jun 22, 2026 · American journal of ophthalmology
Therapeutic response to anti-VEGF retreatment among eyes with stabilized vision after being lost to follow-up in diabetic macular edema: A nationwide, registry-based cohort study
Jun 21, 2026 · American journal of ophthalmology
Zeb1 mediates injury-induced mesenchymal transition in the mouse corneal endothelium in vivo
More in Ophthalmology
View all →Jun 24, 2026 · Lancet (London, England)
Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial
Jun 24, 2026 · The New England journal of medicine
A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
Jun 24, 2026 · The New England journal of medicine
Prevention and Treatment of Peanut Allergy
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
Jun 24, 2026 · The New England journal of medicine
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
Jun 23, 2026 · Lancet (London, England)
Combined bladder-kidney transplantation: first-in-human feasibility trial
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
